



Investor Presentation

May 2021

This presentation has been prepared by Voluntis

Disclaimer : This presentation has been prepared by Voluntis S.A. (the “Company” and, with its subsidiary, the “Group”) and is provided for information purposes only.

This presentation does not constitute an offer to sell securities or investment advisory services or an offer to the public in any country, including France.

The information and opinions contained in this presentation are provided as of the date of this presentation only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes.

The information contained in this presentation has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made by the Company or any of its directors, officers, affiliates or any other such person as to the accuracy, completeness or appropriateness of the information and opinions contained in this presentation. Neither the Company, nor its subsidiaries, advisors, representatives accept any responsibility for and shall not be held liable for any loss or damage that may arise from the use of this presentation or the information or opinions contained herein.

The presentation contains information about the Group in a summarized format. Any decision to purchase or subscribe for securities of the Company shall be taken solely on the basis of the information contained in the 2019 annual financial report and the 2020 half-year financial report published by the Company respectively on April 30, 2020 and September 29, 2020 (a copy of which is available on www.voluntis.com). Your attention is drawn on the risk factors described in such reports.

This presentation contains information on the Group’s markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company’s own estimates. Investors should not base their investment decision on this information.

This presentation contains certain forward-looking statements. These statements are not guarantees of the Group’s future performance. These forward-looking statements relate to the Group’s future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Group’s future performance and the Group’s actual financial position, results and cash flow, as well as the trends in the sector in which the Group operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this presentation. Even if the Group’s financial position, results, cash-flows and developments in the sector in which the Group operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Group’s future results or developments.

The distribution of this document may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.

Voluntis: A Leading Digital Therapeutics (“DTx”) Platform

Our Goal: Improve Treatment Experience and Clinical Outcomes



Medication



Digital therapeutic

- Digital therapeutic solutions helping patients manage their drug therapy
- Regulatory-cleared, clinically-validated solutions
- Real-time patient decision support & increased interaction with care team
- Improved quality of life, treatment adherence, reduced healthcare costs

Multiple Successful Pharmaceutical Partnerships

Industry-leading portfolio of pharma DTx collaborations

abbvie



Bristol Myers Squibb^{MC}



NOVARTIS



Largest rollout of Voluntis solutions in the US

> 100,000 patients

DTx Influencer

Active contributor in advancing DTx reimbursement frameworks

Founding Member of the Digital Therapeutics Alliance

Globally-Scalable Organization

Global organization

Deployments in US, EU & CAN

EU Presence since 2001

US Presence since 2011

1st Publicly Listed DTx Company

on Euronext Growth Paris

ISO 13485 Certified

HIPAA, GDPR Compliant

Management & Board with deep expertise of Life Sciences & Healthcare sectors

Former operational roles and/or Board positions at

GE Medical Systems,
Johnson & Johnson,
Novartis, UCB,
Novo, Elan, Chiesi,
CVS, Prime Therapeutics,
Aetna, Cigna

Seasoned US and EU-Based Management Team

Leadership Team



Pierre Leurent

CEO and Co-founder, Director

22 years experience in digital health in the US & Europe



Romain Marmot

Chief Business Officer, Co-founder

20 years experience in digital health in the US & Europe



Guillaume Floch

Chief Financial Officer

20 years experience in finance in the life sciences industry



Genevieve d'Orsay, MD

Chief Medical Officer

22 years experience in life sciences industry and practicing physician



Etienne Vial

Chief Technology Officer, Co-founder

20 years experience in data analytics, software and medical technology

Board of Directors



Eric Elliott

Chairman

Former CEO of Prime Therapeutics, Executive at Cigna, Aetna



Jan Berger, MD

Director

Former SVP, Chief Clinical Officer and Innovation Officer, CVS Caremark



Viviane Monges

Director

Board member of Novo, UCB, Idorcia, DBV
Former Novartis, Wyeth Executive



Laurent Higuieret

Director

Representing Bpifrance Participations
Previously at BNP Paribas



Franck Noiret

Director

Representing LBO France Gestion
Previously at Apax Partners, EBRD, Societe Generale

International Board of Scientific Advisors (Oncology)



Evan Ya-Wen Yu, MD

Professor of Medical oncology-
Genito-urinary malignancies
Clinical research director,
Seattle Cancer Care Alliance
Seattle, Washington



Joseph Kim, MD

Assistant Professor of Medical
oncology – Genito-urinary
malignancies
Yale University School of Medicine
New Haven, CT



**Dame Lesley Fallowfield,
Pr (FMedSci, DPhil, BSc)**

Professor of Psycho Oncology
University of Sussex
Brighton, UK



Matti Aapro, MD

Medical oncologist,
Dean of Multidisciplinary
Oncology Institute
Genolier Cancer Centre
Switzerland



Karin Jordan, MD, Pr

Professor, in Hematology and
Oncology
University of Heidelberg
Germany



Wei Ai, MD (consultant)

Clinical Assistant Professor, Division of
Hematology/Oncology - Lymphoma
specialist
UCSF
San Francisco, CA



Arvind Dasari, MD

Associate Professor
Gastro-intestinal Medical Oncology
MD Anderson Cancer Center
Houston, TX



Pere Gascón, MD, Pr


Professor, chief of medical oncology, and
scientific coordinator
Hospital Clínic
Barcelona -Spain



Paolo Bossi, MD, Pr

Associate Professor of Medical
Oncology, Head and neck
oncology
University of Brescia, ASST-Spedali
Civili, Brescia, Italy

Revenue Model Delivering Value from Existing DTx Portfolio



Partner	Therapeutic Area
Bristol Myers Squibb [®]	Oncology
Eisai	Oncology
NOVARTIS	Oncology
Biocon	Diabetes
SANOFI	Diabetes
abbvie	Immunology


(1) Including past commercial agreements. Commercial invoicing = Upfront payments, exclusivity payments and perpetual licenses + Development and integration services + SaaS subscriptions, royalties, maintenance & support. Please refer to the Voluntis press release on May 5, 2021.

**Voluntis
Digital
Therapeutics**


Digital Therapeutics: A Global Market with Accelerating Growth

DTx Represents a Significant Market Opportunity

Digital Health Industry Categorization



Digital Therapeutics Market Forecast (in USD Billion)




<https://dtxalliance.org/2019/11/11/digital-health-digital-medicine-digital-therapeutics-dtx-whats-the-difference/>

Source : Grand View Research – Voluntis H1 2020 financial report, Sept 2020

Voluntis Focuses on the Largest Pharmaceutical Markets

2024 Outlook : Pharma Market By Therapeutic Area in USD Billion

(Source : EvaluatePharma 2019)



Oncology, #1 Pharma Market, is Voluntis' #1 Strategic Priority

Therapeutic areas where Voluntis is currently active beyond oncology

Therapeutic areas where Voluntis has developed solutions or has been contacted by Pharma to develop DTx solutions

Traditional Therapies Face Key Challenges and Deliver Suboptimal Outcomes

Key Challenges of Traditional Therapies

Complex Therapies



Administration Challenges



Dosage & Adherence issues

+

At-Home Treatments




Burden of side effects




Limited connection to care team

=

Low Patient Engagement & Poor Outcomes



of cancer patients experience symptoms¹



of Type 2 diabetes patients do not achieve glycemic goals 12 months after insulin initiation²

¹ PLOS. 12(10). DOI: 10.1371/journal.pone.0184360

² Mauricio et al. Diabetes Obesity Metab. 2017;19:1155–1164

Digital Therapeutics Optimize Traditional Therapies


Digitally-Augmented Therapies

Medication



+

DTx



*Supports self-management,
dosing, symptom management
and remote monitoring*

=

Optimized Therapy Improved Outcomes

87%

of #1 side effects
limited to Grade 1 in
oncology clinical trial ¹

X2

Type 2 diabetes
patients achieving
glycemic goals in first 4
months after insulin
initiation²

¹JCO Clinical Cancer Informatics. 2018(2):1-12, 2 doi:10.1111/dom.13806


²Diabetes Obes Metab. 2019;21:2327-2332.

Voluntis' DTx Solutions in Action

How We Help People with Cancer



Reinvent symptom management.




www.oleena.com

How We Help People with Diabetes




Simplify the insulin conversation



www.insulia.com

www.youtube.com/watch?v=LKSOQVfq-Sk

A Scalable DTx Platform




Advanced DTx Analytics Platform




Analytics Platform

Get access to periodic or ad hoc reporting prepared by our Business Intelligence team (PharmDs and data engineers)



Secure APIs

Integrate the structured new dataset with customer analytics tools through secure APIs (RESTful, SOAP)



- Get feedback and insights on **how patients are experiencing their treatment journey**
- Understand which disease / symptom management **best practices to share** across the network
- **Integrate with customer analytics tools**; analyze & improve supportive care strategies & advance research



Patient and HCP usage patterns



Treatment / Symptom reports & associated data




Self-efficacy outcomes




We are proud of our privacy by design approach
All our data hosting and analytics activities comply with HIPAA and GDPR regulations
Our in-house Data Protection Officer is a key member of our design teams

Clinically-Validated and Regulatory Cleared Proprietary DTx


Number of patents filed



Number of clinical studies published ⁽¹⁾



Number of regulatory Clearances obtained



(1) Including studies which results have been communicated as abstracts to date

Solutions Overview
-
Voluntis
Digital Therapeutics
in Oncology

DTx Delivers Significant Value to Cancer Care via Targeted Symptom Management

Cancer in America

15 million People living with cancer in the US in 2016 ⁽¹⁾

90% Patients experience cancer-related symptoms ⁽²⁾

30% Patients on chemotherapy have an ER visit in first 6 months of treatment ⁽³⁾

Cost of Cancer Care

\$170 Billion Total cost of cancer diagnosis and treatment est. in 2020 ⁽⁴⁾

+39% Cost of cancer care since 2010 ⁽⁴⁾

\$25+ Billion Estimated wasteful spending due to unplanned hospitalizations/ED visits ⁽⁵⁾

Symptom management viewed by practices ⁽⁶⁾

#1 Opportunity for cost savings

#1 Most Popular Task performed by Advanced Practitioners

Top 5 Most Popular Service planned via Telehealth in the next 2 years

⁽¹⁾ Cancer Stat Facts: Cancer of Any Site. (2019). NIH National Cancer Institute.

⁽²⁾ PLOS. 12(10). DOI: 10.1371/journal.pone.0184360.

⁽³⁾ Community Cancer Care in Washington State: Quality and Cost Report 2018

⁽⁴⁾ Mariotto, A., et al. (2011). Projections of the cost of cancer care in the United States: 2010-2020.


⁽⁵⁾ All-cause admissions and readmissions 2017. (2017, September 21). National Quality Forum. Company analysis.

⁽⁶⁾ ACCC 2018 Trending Now in Cancer Care Survey Results Highlights https://www.accc-cancer.org/docs/documents/surveys/trends-in-cancer-programs-2018-highlights.pdf?sfvrsn=beaab989_2

The Next-Generation Digital Solution for Cancer Care

Our Vision

Improve adherence by empowering patients to self-manage symptoms, using evidence-based algorithms in order to improve quality of life, treatment exposure, and ultimately increase survival.





- Patient self-management of symptoms with real-time and actionable recommendations
- Combined with remote monitoring by care teams

- Regulated as a medical device
- Prescription-based
- Aligned with value-based care models

Powered by
TheraXium

A First-in-Class Digital Therapeutic in Oncology

Dashboard For Care Teams



Digital Companion For Patients

Personalized configuration based on patient profile

Automated notifications & reports based on patient reported data

Streamlined intervention

Face-to-face visits informed by self-management data

Clinical algorithms Engine

- For a wide range of cancer types and anticancer treatments (incl. chemotherapy, immunotherapies, targeted therapies)
- For most common side effects experienced by patients with cancer, such as diarrhea, pain or nausea/vomiting

Reminders, and reporting of symptoms and metrics

Automated real-time recommendations

Active monitoring

Education and advice adapted to patients needs

Benefits for Patients and Providers

- Empower patients in self-managing symptoms at home
- Trigger timely interventions that may reduce ER visits & hospitalizations
- Help manage symptoms with a goal to optimize treatment exposure and value in real-world


Case Study: Clinical Results obtained in Ovarian Cancer Trial




- Women undergoing treatment for ovarian cancer in clinical trials of the cediranib plus olaparib combination therapy
- Digital companion app paired with wireless blood-pressure monitor and clinician-facing cloud analytics
- Objective is to improve symptom management for PARP+VEGF and aim for integration in drug label
- Research program conducted in partnership with AstraZeneca and the National Cancer Institute

Results presented at ESMO 2017 and published in 2018

JCO® Clinical Cancer Informatics
An American Society of Clinical Oncology Journal



eCO captured 98.2% of required blood pressure measures



Diarrhea events limited to Grade 1


Patients reported:

- High usability (ease of learning, ease of use)
- High satisfaction
- Feeling closely monitored, more connected to their care team, and more involved in self-care

Source : DOI : 10.1200/CCI.17.00153 JCO Clinical Cancer Informatics - publié en ligne le 29 juin 2018

**Voluntis Pharma
Collaborations &
Positioning in DTx**

Digital Therapeutic Co-Development with Pharma



**VOLUNTIS
= DTx LEGAL MANUFACTURER**

- Voluntis leads technology and regulatory activities before and after launch. Voluntis often endorses the legal manufacturer role, with partner control through approval of key deliverables and audits.
- Voluntis may contribute to promotion through support with marketing materials and train-the-trainer programs, and leads the technical operations of the DTx.

**PHARMA
= DISTRIBUTOR**

- Pharma partner leads commercialization.
- In oncology, a DTx is typically launched commercially to thousands, or up to tens of thousands of patients, according to the Partner's molecule profile.

Partnership with Novartis (December 2019)




Voluntis and Novartis announce New Collaboration in Breast Cancer

- Global licensing of Theraxium platform
- Co-development of Digital Therapeutic for Breast Cancer
- Supporting key Novartis Oncology asset

- DTx will enable self-management of symptoms, data analytics and automated triage, remote patient monitoring.

- Upfront and milestone pre-commercialization payments.
- Recurring post-launch per patient revenue.

Based on
Theraxium



Partnership with BMS (March 2020)



- Global licensing of Theraxium platform
- Co-development of multiple Digital Therapeutics
- Supporting large BMS Oncology assets

- DTx will support treatment, provide real-time individualized and algorithms-based recommendations for self-management of symptoms, streamline collaboration with care team.


- EUR 15m ¹ of pre-commercialization revenue (subject in part to milestone events).
- Recurring post-launch per patient revenue.

¹ subject to variations of EUR/USD exchange rate



Voluntis and Bristol-Myers Squibb to Co-Develop Digital Therapeutics For Oncology

Based on
Theraxium



“This collaboration with Voluntis is an example of our commitment to advance patient care with digital solutions. By developing new technology and patient-centered initiatives such as these, we hope to advance the standards of clinical practice.” **Paul von Autenried, CIO, BMS**



Partnership with Biocon Biologics (July 2020)



- Global licensing of Theraxium-based Insulia platform
- Co-development of multiple new diabetes DTx
- Supporting Biocon Biologic insulin portfolio


- DTx will enable self-titration of insulin as well as other features focusing on self-management by patients and remote monitoring by care teams.

- EUR 8m ¹ of pre-commercialization revenue (subject in part to milestone events).
- Recurring post-launch per patient revenue.

¹ subject to variations of EUR/USD exchange rate



Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Diabetes



Based on
 insulia

“We are delighted to collaborate with Voluntis for this unique digital therapeutic solution that has U.S. FDA clearance and CE marked to help manage the treatment of Type 2 diabetes. Biocon Biologics will be one of the first insulin companies globally to offer this innovation for the benefit of people with diabetes.

We believe pairing our products with a digital therapeutic solution will help improve patient outcomes and reduce costs to healthcare systems in the long term. We remain committed to impact patients’ lives through innovative solutions.”

C. Hamacher, CEO, Biocon Biologics

Partnership with Eisai (April 2021)





&



Voluntis to co-develop digital therapeutic with Eisai for people with cancer

- Global licensing of Theraxium platform in oncology with focus on US, JP and EU.
- Oncology DTx aimed to support treatment, provide real-time individualized and algorithms-based recommendations for self-management of symptoms, streamline collaboration with care team.
- Exploration of collaboration opportunities between Voluntis and Eisai in the field of neurology, another area of strategic focus for Eisai notably for Alzheimer's disease and dementia.
- Equity investment alongside of upfront payment upon execution of the agreement.


Based on
Theraxium



"Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions) in our Medium-Term Business Plan "EWAY 2025". Partnering with Voluntis, a leading DTx company, is one of our key initiatives to realize it. We expect this alliance will help increase the benefits provided to patients and their families"
Kazumasa Nagayama, Chief Strategy Officer, Eisai



A Rapidly-Growing Global Footprint























6 markets where Voluntis DTx solutions have been deployed

30 additional markets identified in existing agreements for future DTx commercial launches

2 additional markets under discussion as part of potential future agreements

Voluntis: A Front-Runner Among Digital Therapeutics Pure-Players

	Digital Therapeutics & DTx Platforms Collaborating with Pharma						
							
Therapeutic Areas (main current focus)	<ul style="list-style-type: none"> ▪ Oncology ▪ Diabetes ▪ Immunology 	<ul style="list-style-type: none"> ▪ Substance abuse disorders ▪ Schizophrenia ▪ Insomnia 	<ul style="list-style-type: none"> ▪ ADHD 	<ul style="list-style-type: none"> ▪ Diabetes 	<ul style="list-style-type: none"> ▪ Depression ▪ Schizophrenia ▪ Smoking cessation 	<ul style="list-style-type: none"> ▪ Cardiology ▪ Oncology 	<ul style="list-style-type: none"> ▪ Diabetes ▪ Hematology ▪ Cardiovascular ▪ Respiratory ▪ Nephrology
Regulatory Approvals (as manufacturer)							
Current Life Sciences Partnerships							
Global Footprint	US, CAN, EU, JP	US	US, JP	US, CAN, JP	US	US, SG	US, EU

Notes: ADHD (Attention deficit hyperactivity disorder)

Financial Performance

Growth of commercial potential between 2011 and 2020




(1) Cumulative peak sales of molecules with which digital therapeutics are associated (DTx at development stage in the portfolio of pharmaceutical collaborations).

From Sales Invoicing to Revenues : Illustrative View of a Contract

IFRS 15

Sales invoicing





Revenues



Development Phase
 Sales invoicing (upfront + milestones)
but limited IFRS revenues recognized
(partial recognition of milestones payments)
 Phase from 6 month to 3 years in general

Commercial Phase
 Sales invoicing (primarily royalties)
and IFRS revenues reinforced with sales invoicing from previous years
(recognition of upfront + milestones + royalties)
 Maximum duration of commercialization recorded to date : 10 years


Focus on 2020 financial performance



Source : Voluntis financial activity for 2020 (audited figures)

From Sales Invoicing to Revenues

Deferred revenue evolution (€ M)



Comments

- 1 The majority of the sales invoicing over the period will be deferred, and therefore leads to increasing the « stock » of deferred revenues
- 2 Revenue recognition leads to a decrease in the « stock » of deferred revenues

Income Statement as of December 31, 2020


<i>In thousands of euros - Audited data</i>	31/12/2019	31/12/2020
Revenue	3 660	4 398
1 Other Operating Income	1 012	791
Total Income	4 672	5 189
2 Labor Costs	(11 430)	(9 133)
3 Other Operating Expenses	(5 758)	(5 108)
Operational Depreciations	(2 312)	(2 052)
Operating profit	(14 827)	(11 103)
Financial income	(986)	(718)
Taxes	(0)	(303)
Net income (group share)	(15 813)	(12 124)
EBITDA	(12 515)	(9 051)
4 Adjusted EBITDA	(13 365)	(3 354)

Comments

- 1 Including R&D tax credit
- 2 Labor costs: Organizational adaptation plan launched in March 2020, having already partially produced its effects by the end of June 2020 (particularly in the US)
- 3 Other Operating Expenses : The change in this item is explained by the change in subcontracting expenses in connection with the restructuring plan that began in March 2020 and by the decrease in travel and transportation expenses related to the Covid-19 crisis that began in March 2020
- 4 Adjusted EBITDA: Significant improvement for the year thanks to higher revenues and lower operating expenses.

The Adjusted EBITDA is an Alternative Performance Indicator corresponding to the EBITDA amended with the variation in prepaid income and deferred charges pursuant to the application of IFRS 15 (income invoiced for items over which control has not been transferred, expenses for the execution of items produced under customer contracts and not yet transferred).

Doubling of Cash Position



Cash Position

Voluntis is able to cover its financial needs beyond the next 12 months ⁽¹⁾

(1) No intent to use the flexible bond financing facility ("OCEANE-BSA") obtained on March 23, 2020, not used to date and for which the drawing possibility, at the exclusive initiative of Voluntis, will expire on September 23, 2021

Cash Flow Statement as of December 31, 2020

<i>In thousands of euros - Audited data</i>	31/12/2019	31/12/2020
1 <i>Net cash flows from/(used in) operating activities</i>	(12 168)	(1 372)
<i>Net cash flows from/(used in) investing activities</i>	(2 147)	(749)
2 <i>Net cash flow from/(used in) financing activities</i>	(347)	8 021
CASH FLOW VARIATION	(14 662)	5 900
Net foreign exchange difference	2	(11)
OPENING CASH BALANCE	19 783	5 121
CLOSING CASH BALANCE	5 122	11 010

Comments

1 Cash flows from operating activities:

- The increase in cash flow is related to the partnerships formed and the strategic reduction in the cost structure.

2 Cash flows from investing activities :

- The increase in this line is linked to the company's subscription to a €5.0 million PGE (state-guaranteed loan) and to a €1.0 million R&D Innovation loan from Bpifrance, and a €5.9 million private placement fundraising in November 2020, which notably allowed Debiopharm Innovation Fund, a corporate fund of the Swiss company Debiopharm, to acquire a stake in Voluntis, as well as the strengthening in the capital of Indigo, the personal holding company of Eric Carreel, Chairman and co-founder of Withings.
- Voluntis believes it has the necessary resources to cover its financial needs, at least over the next 12 months, without recourse to new financing.

Balance Sheet as of December 31, 2020

<i>In thousands of euros - Audited data</i>	31/12/2019	31/12/2020
Assets		
Intangible assets	2 694	2 071
Tangible assets	3 313	405
Non-current financial assets	258	251
1 Other non-current assets	364	1 091
<i>Non current assets</i>	<i>6 629</i>	<i>3 817</i>
Receivables	541	844
Other current financial assets	-	-
2 3 Other current assets	4 984	2 180
Cash on hand	5 121	11 010
<i>Current assets</i>	<i>10 647</i>	<i>14 035</i>
Total	17 277	17 852
	31/12/2019	31/12/2020
Liabilities		
4 <i>Shareholder equity</i>	<i>1 742</i>	<i>(4 629)</i>
Financial debt (non current)	4 452	6 062
5 LT provisions and other non current liabilities	852	7 219
<i>Non current liabilities</i>	<i>5 304</i>	<i>13 281</i>
Financial debt (current)	3 201	2 088
6 Payables and other current liabilities	7 029	7 112
<i>Current liabilities</i>	<i>10 230</i>	<i>9 200</i>
Total	17 277	17 852


Comments

- 1 2 Assets on non-current contracts: with customers for €1,091k represent the portion of contract execution costs due in more than one year, spread according to IFRS 15. The current portion is recorded in assets on current contracts for an amount of €162k
- 3 R&D tax Credit: for the year 2020, representing a total amount of €1,109k, is recorded in other current assets as of December 31, 2020.
- 4 Shareholders' equity: A private placement was carried out in November 2020 for €5.9 million
- 5 6 Deferred income: resulting from the application of IFRS 15 ; €6,742k are booked in the other non current liabilities, and €3,154k in the other current liabilities, i.e. a total of €9,9M.

Shareholder Structure and Stock Information

Shareholder Structure

Share Repartition as of early May 2021⁽¹⁾




*Board Director

**Board Observer

Stock Information

Market : Euronext Growth Paris




- Average Daily Volume from May 1, 2020 to April 30, 2021: 110,000 shares (€ 411k in transaction)
- Voluntis transferred the listing of its shares to Euronext Growth Paris on February 17, 2021.

(1) Share repartition after finalization of the equity raise with Eisai

**Exciting Future
Growth Opportunities**

Profitable growth trajectory through 2025 and beyond




Confirmation of 2021 objectives

- Commercial invoicing between € 8 and 12 million
- Positive Free Cash Flow in H2 2021

(1) Based on the commercial rollout of solutions, negotiated per patient fees and forecasted numbers of end-users

(2) Thanks to the commercial ramp-up and the Theraxium platform scalability

Vast Potential of Value Creation for Shareholders



5 reasons to be a shareholder

1

A booming, global digital therapeutics market offering significant growth opportunities within core and new therapeutic areas

2

A robust and replicable technology platform supporting an extensive suite of companion digital therapeutics solutions

3

A flagship portfolio of DTx under development with tier-1 pharmaceutical companies

4

An attractive financial trajectory of profitable growth

5

Additional value-creation opportunities with enhanced offering for pharma partners and expansion beyond pharma

Thank you for your attention!

Investor contact:

voluntis@actus.fr

Company contact:

investors@voluntis.com

